Event-Driven Stocks

Lyell Immunopharma, Inc.

LYELNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$36,000$61,000$130,000$84.7M$10.7M$7.8M
Operating income−$269.4M−$358.8M−$247.0M−$187.1M−$214.8M−$211.9M
Net income−$274.4M−$343.0M−$234.6M−$183.1M−$250.2M−$204.5M
Total assets$340.1M$490.9M$750.0M$937.6M$1.13B$908.3M
Total liabilities$91.8M$108.0M$95.1M$104.3M$197.6M$189.8M
Equity$248.2M$382.8M$655.0M$833.3M$929.8M−$292.5M
EPS (diluted)$-16.06$-26.23$-18.70$-0.74$-1.84$-15.69
Shares out.295.2M254.1M249.6M245.4M242.7M15.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−748344.4%
Net margin
−762355.6%
Return on equity
−110.6%
Return on assets
−80.7%
Return on capital (ROCE)
−92.7%
Liabilities / assets
27.0%
Debt / equity
0.37×
Book value / share
$0.84
Revenue growth (YoY)
−41.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-13.93distress
Accruals / assets
−36.6%clean
Piotroski F-Score
1/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
35
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.3M23.3-0.3%
Apr 30, 20261.3M18.8+8.9%
Apr 15, 20261.2M12.0+8.4%
Mar 31, 20261.1M12.8+21.1%
Mar 13, 2026940,2698.6+15.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)